Clinical trials assessing therapeutic IgM for a variety of non-communicable diseases such as arthritis and cancer have shown good safety profiles, though efficacy has been limited to date, perhaps due to the use of low affinity, non-affinity matured IgM antibodies (38). Here, CD40LG is linked to arthritic joint disease.